

North Central Cancer Treatment Group

N0572: A Phase I/II Study of Sorafenib and CCI-779 in Patients with Recurrent Glioblastoma

Revised Status Change – December 15, 2006

**NOTICE OF STATUS CHANGE**

The Phase I portion of this study will reopen for 3 patients at dose level 1 (Sorafenib 400 mg, CCI-779 25 mg) effective, Friday, December 15, 2006.

**Please retain this notice with the protocol.**